

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: Västra Götaland**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	2782	62.1%	513	11.4%	417	9.3%	144	3.2%	625	13.9%	4481	100.0%
<i>Tecken på HPV-infektion</i>	50	61.0%	16	19.5%	7	8.5%	.	.	9	11.0%	82	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	399	30.3%	410	31.1%	248	18.8%	2	0.2%	258	19.6%	1317	100.0%
<i>Lätt skivepiteltypi</i>	818	31.6%	592	22.9%	792	30.6%	14	0.5%	372	14.4%	2588	100.0%
<i>Lätt dysplasi / CIN 1</i>	208	19.7%	361	34.2%	415	39.3%	.	.	73	6.9%	1057	100.0%
<i>Körtelcellsatypi</i>	29	36.7%	6	7.6%	11	13.9%	21	26.6%	12	15.2%	79	100.0%
<i>Oklar atypi</i>	21	38.9%	5	9.3%	19	35.2%	5	9.3%	4	7.4%	54	100.0%
<i>Misstänkt höggradig dysplasi</i>	23	9.0%	22	8.6%	192	75.3%	5	2.0%	13	5.1%	255	100.0%
<i>Måttlig dysplasi / CIN 2</i>	68	9.4%	80	11.0%	545	75.1%	9	1.2%	24	3.3%	726	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	17	3.2%	19	3.6%	471	88.5%	14	2.6%	11	2.1%	532	100.0%
<i>Adenocarcinom / AIS</i>	.	.	1	2.6%	11	28.2%	26	66.7%	1	2.6%	39	100.0%
<i>Mal. tumör oklart urspr.</i>	.	.	.	.	.	.	3	100.0%	.	.	3	100.0%
<i>Skivepitelcancer</i>	2	22.2%	.	.	4	44.4%	3	33.3%	.	.	9	100.0%
<i>Totalt</i>	4417	39.4%	2025	18.0%	3132	27.9%	246	2.2%	1402	12.5%	11222	100.0%

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: NÄL**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	364	76.2%	30	6.3%	27	5.6%	20	4.2%	37	7.7%	478	100.0%
<i>Tecken på HPV-infektion</i>	32	62.7%	10	19.6%	3	5.9%	.	.	6	11.8%	51	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	134	42.1%	103	32.4%	42	13.2%	.	.	39	12.3%	318	100.0%
<i>Lätt skivepitelatyperi</i>	81	43.8%	49	26.5%	35	18.9%	.	.	20	10.8%	185	100.0%
<i>Lätt dysplasi / CIN 1</i>	68	22.7%	118	39.5%	91	30.4%	.	.	22	7.4%	299	100.0%
<i>Körtelcellsatypi</i>	2	14.3%	1	7.1%	3	21.4%	6	42.9%	2	14.3%	14	100.0%
<i>Oklar atypi</i>	.	.	.	.	3	100.0%	.	.	.	.	3	100.0%
<i>Misstänkt höggradig dysplasi</i>	.	.	.	.	2	100.0%	.	.	.	.	2	100.0%
<i>Måttlig dysplasi / CIN 2</i>	8	5.8%	15	10.9%	109	79.0%	1	0.7%	5	3.6%	138	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	4	8.5%	1	2.1%	41	87.2%	1	2.1%	.	.	47	100.0%
<i>Adenocarcinom / AIS</i>	.	.	.	.	3	50.0%	3	50.0%	.	.	6	100.0%
<i>Totalt</i>	693	45.0%	327	21.2%	359	23.3%	31	2.0%	131	8.5%	1541	100.0%

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: SU**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	1374	53.8%	335	13.1%	270	10.6%	73	2.9%	502	19.7%	2554	100.0%
<i>Tecken på HPV-infektion</i>	3	75.0%	.	.	.	.	.	.	1	25.0%	4	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	241	25.9%	288	30.9%	188	20.2%	2	0.2%	213	22.9%	932	100.0%
<i>Lätt skivepitelatyperi</i>	395	24.3%	359	22.1%	562	34.6%	8	0.5%	299	18.4%	1623	100.0%
<i>Lätt dysplasi / CIN 1</i>	37	14.9%	68	27.4%	112	45.2%	.	.	31	12.5%	248	100.0%
<i>Körtelcellsatypi</i>	11	37.9%	1	3.4%	4	13.8%	8	27.6%	5	17.2%	29	100.0%
<i>Oklar atypi</i>	.	.	.	.	.	.	1	100.0%	.	.	1	100.0%
<i>Misstänkt höggradig dysplasi</i>	7	4.5%	16	10.3%	123	79.4%	2	1.3%	7	4.5%	155	100.0%
<i>Måttlig dysplasi / CIN 2</i>	11	4.9%	12	5.3%	186	82.3%	4	1.8%	13	5.8%	226	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	7	2.5%	13	4.6%	246	86.9%	9	3.2%	8	2.8%	283	100.0%
<i>Adenocarcinom / AIS</i>	.	.	1	6.3%	6	37.5%	8	50.0%	1	6.3%	16	100.0%
<i>Skivepitelcancer</i>	.	.	.	.	4	57.1%	3	42.9%	.	.	7	100.0%
<i>Totalt</i>	2086	34.3%	1093	18.0%	1701	28.0%	118	1.9%	1080	17.8%	6078	100.0%

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: Borås**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	429	73.3%	55	9.4%	31	5.3%	19	3.2%	51	8.7%	585	100.0%
<i>Tecken på HPV-infektion</i>	7	53.8%	3	23.1%	2	15.4%	.	.	1	7.7%	13	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	3	27.3%	7	63.6%	1	9.1%	.	.	.	.	11	100.0%
<i>Lätt skivepitelatypti</i>	94	33.6%	85	30.4%	78	27.9%	3	1.1%	20	7.1%	280	100.0%
<i>Lätt dysplasi / CIN 1</i>	44	18.1%	95	39.1%	94	38.7%	.	.	10	4.1%	243	100.0%
<i>Körtelcellsatypti</i>	6	35.3%	3	17.6%	2	11.8%	2	11.8%	4	23.5%	17	100.0%
<i>Oklar atypi</i>	9	33.3%	2	7.4%	11	40.7%	1	3.7%	4	14.8%	27	100.0%
<i>Misstänkt höggradig dysplasi</i>	8	15.7%	6	11.8%	35	68.6%	1	2.0%	1	2.0%	51	100.0%
<i>Måttlig dysplasi / CIN 2</i>	39	15.7%	46	18.5%	155	62.5%	3	1.2%	5	2.0%	248	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	4	3.8%	3	2.9%	93	89.4%	2	1.9%	2	1.9%	104	100.0%
<i>Adenocarcinom / AIS</i>	.	.	.	.	2	15.4%	11	84.6%	.	.	13	100.0%
<i>Mal. tumör oklart urspr.</i>	.	.	.	.	.	.	3	100.0%	.	.	3	100.0%
<i>Skivepitelcancer</i>	2	100.0%	.	.	.	.	.	.	.	.	2	100.0%
<i>Totalt</i>	645	40.4%	305	19.1%	504	31.6%	45	2.8%	98	6.1%	1597	100.0%

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: Skövde**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	615	71.2%	93	10.8%	89	10.3%	32	3.7%	35	4.1%	864	100.0%
<i>Tecken på HPV-infektion</i>	8	57.1%	3	21.4%	2	14.3%	.	.	1	7.1%	14	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	21	37.5%	12	21.4%	17	30.4%	.	.	6	10.7%	56	100.0%
<i>Lätt skivepitelatyperi</i>	248	49.6%	99	19.8%	117	23.4%	3	0.6%	33	6.6%	500	100.0%
<i>Lätt dysplasi / CIN 1</i>	59	22.1%	80	30.0%	118	44.2%	.	.	10	3.7%	267	100.0%
<i>Körtelcellsatypi</i>	10	52.6%	1	5.3%	2	10.5%	5	26.3%	1	5.3%	19	100.0%
<i>Oklar atypi</i>	12	52.2%	3	13.0%	5	21.7%	3	13.0%	.	.	23	100.0%
<i>Misstänkt höggradig dysplasi</i>	8	17.0%	.	.	32	68.1%	2	4.3%	5	10.6%	47	100.0%
<i>Måttlig dysplasi / CIN 2</i>	10	8.8%	7	6.1%	95	83.3%	1	0.9%	1	0.9%	114	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	2	2.0%	2	2.0%	91	92.9%	2	2.0%	1	1.0%	98	100.0%
<i>Adenocarcinom / AIS</i>	.	.	.	.	.	.	4	100.0%	.	.	4	100.0%
<i>Totalt</i>	993	49.5%	300	15.0%	568	28.3%	52	2.6%	93	4.6%	2006	100.0%

**Histopatologiskt utfall inom 12 månader av all cytologi från 2011 som följts upp med histopatologi: Halmstad**

	<i>Histopatologi</i>											
	<i>Benigt</i>		<i>CIN1</i>		<i>CIN2-3</i>		<i>Cancer</i>		<i>Annat</i>		<i>Totalt</i>	
	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>	<i>Antal</i>	<i>Andel</i>
<i>Cytologi</i>												
<i>Benigt prov</i>	490	72.0%	44	6.5%	50	7.3%	34	5.0%	63	9.3%	681	100.0%
<i>ASCUS + Tecken på HPV-infektion</i>	16	43.2%	13	35.1%	6	16.2%	.	.	2	5.4%	37	100.0%
<i>Lätt skivepitelatypi</i>	189	50.1%	81	21.5%	74	19.6%	1	0.3%	32	8.5%	377	100.0%
<i>Lätt dysplasi / CIN 1</i>	111	38.8%	68	23.8%	85	29.7%	1	0.3%	21	7.3%	286	100.0%
<i>Körtelcellsatypi</i>	9	56.3%	.	.	6	37.5%	1	6.3%	.	.	16	100.0%
<i>Oklar atypi</i>	5	38.5%	.	.	7	53.8%	.	.	1	7.7%	13	100.0%
<i>Misstänkt höggradig dysplasi</i>	3	15.8%	1	5.3%	14	73.7%	1	5.3%	.	.	19	100.0%
<i>Måttlig dysplasi / CIN 2</i>	16	10.5%	12	7.9%	117	77.0%	3	2.0%	4	2.6%	152	100.0%
<i>Stark dysplasi / CIN 3 / CIS</i>	2	2.7%	1	1.3%	67	89.3%	5	6.7%	.	.	75	100.0%
<i>Adenocarcinom / AIS</i>	.	.	.	.	.	.	1	100.0%	.	.	1	100.0%
<i>Skivepitelcancer</i>	.	.	.	.	1	33.3%	2	66.7%	.	.	3	100.0%
<i>Totalt</i>	841	50.7%	220	13.3%	427	25.7%	49	3.0%	123	7.4%	1660	100.0%